Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
  • Patent number: 12006367
    Abstract: The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: June 11, 2024
    Assignee: Ichnos Sciences SA
    Inventors: Romain Ollier, Samuel Hou, Rami Lissilaa, Darko Skegro, Jonathan Back
  • Patent number: 11986525
    Abstract: Provided herein is a method of treating a traumatic brain injury in a subject in need thereof, the method including administering to the subject a therapeutically effective amount of radiation. The methods can improve motor function recovery and reverse motor function deficits after traumatic brain injury and/or ischemic stroke in a subject.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: May 21, 2024
    Assignee: City University of Hong Kong
    Inventors: Chi Him Eddie Ma, Ngan Pan Bennett Au
  • Patent number: 11980669
    Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: May 14, 2024
    Assignee: Pfizer, Inc.
    Inventors: Xiaotian Zhong, Amarnauth Shastrie Prashad, Ronald William Kriz, Tao He, Will Somers, Wenge Wang, Leo Joseph Letendre
  • Patent number: 11976133
    Abstract: Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: May 7, 2024
    Assignee: Gensun Biopharma Inc.
    Inventors: Margaret Karow, Richard Yau, Jackie Sheng
  • Patent number: 11969476
    Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: April 30, 2024
    Assignee: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Kenneth Douglas Johnson, Obadiah Joseph Plante, James C. Delaney, Tyree J. Koch, Hamid Tissire, Andrew M. Wollacott, Boopathy Ramakrishnan
  • Patent number: 11965023
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: April 23, 2024
    Assignee: Alector LLC
    Inventors: Kate Monroe, Helen Lam, Patricia Culp, Arnon Rosenthal
  • Patent number: 11965024
    Abstract: Anti-V?17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: April 23, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rajkumar Ganesan, Iqbal S. Grewal, Sanjaya Singh, Michael Riis Hansen
  • Patent number: 11952429
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: April 9, 2024
    Inventors: J. Andrew Bristol, Judith A. Kantor
  • Patent number: 11897952
    Abstract: Provided herein are functionalized monoclonal antibodies (mAbs) including antibody fragments, including those where a Fab-binding molecule (Fab binding moiety) linked to a steric hindering molecule (steric hindering chemical moiety) is mechanically interlocked (e.g., through noncovalent conjugation) with the antibody or antibody fragment. Also provided are compositions that form highly stable and versatile drug delivery and diagnostic compositions.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: February 13, 2024
    Inventors: John Williams, Krzysztof P. Bzymek, David Horne, Jun Xie
  • Patent number: 11850216
    Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolabeled proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: December 26, 2023
    Assignees: Whitehead Institute for Biomedical Research, The General Hospital Corporation
    Inventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
  • Patent number: 11826436
    Abstract: A method for preparing a complex comprising a radioisotope of gallium for use in radiotherapy or in a medical imaging procedure, said method comprising adding a gallium radioisotope solution obtained directly from a gallium radionuclide generator to a composition comprising a pharmaceutically acceptable buffer and optionally also a pharmaceutically acceptable basic reagent, in amounts sufficient to increase the pH to a level in the range of 3 to 8, wherein the composition further comprises a chelator that is able to chelate radioactive gallium within said pH range and at moderate temperature, said chelator being optionally linked to a biological targeting agent. Kits and compositions for use in the method are also described and claimed.
    Type: Grant
    Filed: July 5, 2022
    Date of Patent: November 28, 2023
    Inventors: Philip Blower, Gregory Mullen
  • Patent number: 11814437
    Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.
    Type: Grant
    Filed: October 6, 2022
    Date of Patent: November 14, 2023
    Assignee: GENMAB A/S
    Inventors: David Satijn, Patrick Engelberts, Kristel Kemper, Esther C. W. Breij, Simone Oostindie, Farshid Alemdehy
  • Patent number: 11802152
    Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: October 31, 2023
    Assignee: Novartis AG
    Inventors: Brian Boettcher, Shari Lynn Caplan, Regis Cebe, Guochun Li, John A. Taraszka, Fangmin Xu, David Langdon Yowe
  • Patent number: 11795228
    Abstract: The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: October 24, 2023
    Assignee: Dren Bio, Inc.
    Inventors: Nenad Tomasevic, Ruo Shi Shi
  • Patent number: 11744908
    Abstract: Methods for determining systemic biodistribution characteristics of intravitrially administered medicaments. In some embodiments, radiolabeled agents or medicaments, such as I-124 labeled bevacizumab, ranibizumab and aflibercept, was imaged utilizing PET/CT in a non-human primate model, with radioactivity emission measurements made to determine the intravitreal half-lives of each agent and to determine the differences of radioactivity uptake in non-ocular organs.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: September 5, 2023
    Inventors: John Christoforidis, Michael Knopp
  • Patent number: 11739150
    Abstract: Provided are anti-CD8 antibodies that bind human CD8 and do not stimulate or inhibit the activation of CD8+ T cells. Also provided are nucleic acids encoding such anti-CD8 antibodies, vectors comprising such nucleic acids, host cells comprising same, and methods of making such anti-CD8 antibodies. Also provided are anti-CD8 antibodies conjugated to a detectable label. Provided are methods of using such anti-CD8 antibodies to detect CD8+ T cells in a subject, monitor disease progress in a subject having cancer, and monitor treatment progress in a subject having cancer.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: August 29, 2023
    Assignee: Genentech, Inc.
    Inventors: Yvonne M. Chen, Eugene Yu-Chuan Chiang, Jane Louise Grogan, Simon-Peter Williams, Matthew Lawrence Albert
  • Patent number: 11690874
    Abstract: Embodiments of the present disclosure include a method for treating Systemic Lupus Erythematosus (SLE) using CD19 CAR T cells. The method includes administering to the human patient a pharmaceutically effective amount of a population of T cells of the human patient that express a chimeric antigen receptor (CAR) that comprises the amino acid sequence of, e.g., SEQ ID NO: 23.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: July 4, 2023
    Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Zhejiang University
    Inventors: Lei Xiao, Chengfei Pu, Zhao Wu, Linrong Lu
  • Patent number: 11692046
    Abstract: The present disclosure relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: July 4, 2023
    Assignee: Novartis AG
    Inventors: Regis Cebe, Stephane Olland, David Langdon Yowe
  • Patent number: 11667707
    Abstract: The purpose of the present invention is to provide an antibody that can be expected to have a therapeutic effect in autoimmune diseases and anticancer treatment by inhibiting S1P transport by SPNS2 to thereby inhibit lymphocyte migration. The present invention is an SPNS2 neutralizing antibody or a fragment thereof, or a derivative thereof, that specifically binds to vertebrate SPNS2 and has lymphocyte migration inhibitory activity through SW transport inhibition.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: June 6, 2023
    Assignee: Teijin Pharma Limited
    Inventors: Kenta Hibiya, Yusuke Kanamaru, Hirotsugu Kato
  • Patent number: 11666672
    Abstract: Disclosed is a non-invasive PET-CT imaging method for detecting acute myeloid leukemia (AML) or extramedullary disease (EMD) in a subject using a radioactive isotope-labeled anti-CD33 antibody. Also disclosed is a PET-CT imaged-guided method for treating AML or EMD.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: June 6, 2023
    Assignee: CITY OF HOPE
    Inventors: Susanta Kumar Hui, Paul J. Yazaki, Srideshikan Sargur Madabushi
  • Patent number: 11655298
    Abstract: It is an object to provide effective means for preventing and/or treating fulminant acute pneumonia. Provided are a pharmaceutical agent or pharmaceutical composition to be used for preventing and/or treating fulminant acute pneumonia, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing intra-alveolar neutrophil aggregation, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing pulmonary neutrophil infiltration, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), and a method of preventing and/or treating fulminant acute pneumonia, including administering a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody).
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: May 23, 2023
    Assignees: YAMAGUCHI UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Akihiro Hasegawa, Hidetaka Ogino, Toshinori Nakayama
  • Patent number: 11649490
    Abstract: The invention relates to a new method of determining the presence, absence or one or more characteristics of multiple analytes. The invention concerns coupling a first analyte to a membrane containing a detector and investigating the first analyte using the detector. The invention also concerns coupling a second analyte to the membrane and investigating the second analyte. The first analyte is uncoupled form the membrane prior to investigating the second analyte. The invention also relates to polynucleotide sequencing.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: May 16, 2023
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: James Anthony Clarke, Marion Louise Crawford, James White
  • Patent number: 11644473
    Abstract: The present disclosure is directed to methods and kits for using serum biomarkers, including C-X-C Motif Chemokine Ligand 10 (CXCL10), C-X-C Motif Chemokine Ligand 13 (CXCL13), and/or soluble CD27 (sCD27), in predicting and evaluating therapeutic response to Tumor Necrosis Factor (TNF) inhibitor therapy in a patient in need thereof.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 9, 2023
    Assignee: Rowan University
    Inventors: Kwanghoon Han, Andrea Bottaro, Nancy J. Olsen
  • Patent number: 11618878
    Abstract: The present invention concerns a single use aseptic kit comprising: a disaggregation module for receipt and processing of material comprising solid mammalian tissue; and a stabilisation module for storing disaggregated product material, wherein each of said modules comprises one or more flexible containers connected by one or more conduits adapted to enable flow of the tissue material there between; and wherein each of said modules comprises one or more ports to permit aseptic input of media and/or reagents into the one or more flexible containers. The invention further relates to an automated device for semi-automated aseptic disaggregation and/or enrichment and/or stabilisation of cells or cell aggregates from mammalian solid tissue comprising a programmable processor and the single use aseptic kit. The invention further relates to a semi-automatic aseptic tissue processing method.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: April 4, 2023
    Assignee: INSTIL BIO (UK) LIMITED
    Inventor: Ryan Dominic Guest
  • Patent number: 11603411
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 14, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Patent number: 11590128
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: February 28, 2023
    Assignees: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Patent number: 11561224
    Abstract: The invention generally relates to methods for predicting responsiveness of a cancer to an immunotherapeutic agent and methods of treating cancer. More specifically, the invention relates in part to the use of histone H3 lysine (27) trimethylation (H3K27me3), E-cadherin, and other biomarkers to treat cancer and determine the responsiveness of a cancer tumor to treatment with an immunotherapeutic agent.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: January 24, 2023
    Assignee: BIOVENTURES, LLC
    Inventors: Bradley Shields, Alan Tackett, Stephanie Byrum, Fade Mahmoud, Sara Shalin
  • Patent number: 11541047
    Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: January 3, 2023
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, David M. Goldenberg
  • Patent number: 11530259
    Abstract: The disclosure provides for methods and treatments of TLR2-mediated diseases and disorders comprising administering an antibody, antibody fragment, or polypeptide that binds to and inhibits the biological activity of oxidized phospholipids.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: December 20, 2022
    Assignee: The Regents of the University of California
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • Patent number: 11524178
    Abstract: Parameterized model reconstruction is used for internal dose tomography. The parameterized model, solved for within the reconstruction, models the dose level and may account for diffusion, isotope half-life, and/or biological half-life. Using the detected emissions from different scans (e.g., from different scan sessions in a given cycle) as input for the one reconstruction, the parameterized model reconstruction determines the biodistribution of dose at any time.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: December 13, 2022
    Assignee: Siemens Medical Solutions USA, Inc.
    Inventors: Alexander Hans Vija, Michal Cachovan
  • Patent number: 11517632
    Abstract: Provided are an anti-Her2 nanobody and a coding sequence and the use thereof. In particular, provided is a nanobody combating human epidermal growth factor receptor-2 (Her2/ERBB2). Disclosed are the nanobody and the a gene sequence encoding the nanobody, a corresponding expression vector and a host cell capable of expressing the nanobody, and a method for producing the nanobody of the present invention and the related use thereof. The present invention may also provide an immunoconjugate of the nanobody and the use thereof, especially the use in the diagnosis and treatment of Her2 positive tumor.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: December 6, 2022
    Assignee: NANOMAB TECHNOLOGY LIMITED
    Inventors: Hong Hoi Ting, Chung Lim Wong, Wenhua Huang
  • Patent number: 11497818
    Abstract: The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: November 15, 2022
    Assignees: NANOH, UNIVERSITE LYON 1 CLAUDE BERNARD, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON
    Inventors: François Lux, Olivier Tillement, Maxime Saint Jean, Pierre Mowat, Pascal Perriat, Stéphane Roux, Anna Mignot
  • Patent number: 11466077
    Abstract: The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disorder and/or abnormality associated with misfolded TDP-43 including but not limited to frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD, sporadic and familial), and/or Parkinson's disease (PD). The present invention provides modified conformation-specific antigenic peptides and peptide fragments derived from the TDP-43 protein and the antibodies obtainable by said peptides or fragments for use in the diagnosis, prevention, alleviation and/or treatment of TDP-43-related disorders and/or abnormalities.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: October 11, 2022
    Assignee: AC Immune SA
    Inventors: Tamara Seredenina, Oskar Adolfsson
  • Patent number: 11459398
    Abstract: Provided are conjugates including a targeting moiety that binds to a cell surface molecule of a target cell and a target cell surface-editing enzyme. Also provided are compositions and kits that include the conjugates, as well as methods of using the conjugates. Methods of making conjugates are also provided.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 4, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Elliot C. Woods, Han Xiao, Carolyn R. Bertozzi, Melissa Gray
  • Patent number: 11447573
    Abstract: Disclosed herein are multispecific, such as bispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, and a second antigen binding domain comprising a single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: September 20, 2022
    Assignee: NANJING LEGEND BIOTECH CO., LTD.
    Inventors: Chuan-Chu Chou, Yafeng Zhang, Shu Wu, Zhenyu Liu, Zhongdao Li, Fangliang Zhang
  • Patent number: 11426471
    Abstract: Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: August 30, 2022
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Jenny Jie Yang, Fan Pu, Shenghui Xue, Jingjuan Qiao, Shanshan Tan, Mani Salarian
  • Patent number: 11420910
    Abstract: New chelators such as H3L1, H3L2, H3L3, H3L26 and derivatives were synthesized for the complexation of {Al18F}2+. These new chelators are able to complex {AI18F}2+ with good radiochemical yields using a labeling temperature of 37° C. The stability of the new Al18F-complexes was tested in phosphate buffered saline (PBS) at pH 7 and in rat serum. AI18F-L3 and AI18F-L26 showed a stability comparable to that of the previously reported Al18F-NODA. Moreover, the biodistribution of Al18F-L3 and AI18F-L26 showed absence of in vivo demetallation since only very limited bone uptake was observed, whereas the major fraction of activity 60 min p.i. was observed in liver and intestine due to hepatobiliary clearance of the radiolabeled ligand. The chelators H3L3 and Al18F-L26 demonstrated to be a good lead candidates for the labeling of heat sensitive biomolecules with 18F-fluorine and derivatives have been synthesized.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: August 23, 2022
    Assignee: KATHOLIEKE UNIVERSITET LEUVEN
    Inventors: Ahamed Muneer Syed Musthakahmed, Emilie Billaud, Guy Bormans, Frederik Cleeren, Joan Lecina, Alfons Verbruggen
  • Patent number: 11401333
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: August 2, 2022
    Assignee: GENENTECH, INC.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • Patent number: 11359025
    Abstract: Provided herein are antibodies specific for Interleukin-1 receptor accessory protein (IL1-RAP).
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: June 14, 2022
    Assignee: Cantargia AB
    Inventors: Ying Ping Jiang, Jagath R. Junutula, Leonard G. Presta
  • Patent number: 11360092
    Abstract: The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: June 14, 2022
    Assignees: The Research Foundation for The State University of New York, KDx Diagnostics, Inc.
    Inventors: Kenneth R. Shroyer, Luisa F. Escobar-Hoyos, Nam Kim
  • Patent number: 11351234
    Abstract: An object of the present invention is to provide a vaccine that can simultaneously reduce A? deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA encoding amyloid-?, DNA encoding an immunoglobulin Fc sequence, and DNA encoding tau.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: June 7, 2022
    Assignee: IMMUNOTHERAPY DEVELOPMENT INC.
    Inventor: Yoh Matsumoto
  • Patent number: 11344638
    Abstract: The invention provides a compound having the following structure: T-DOTA-R, wherein T is a carbohydrate polymer, R is a radioactive isotope, DOTA is a chelator of R, and T is covalently bond to DOTA. In one embodiment, the carbohydrate polymer is hyaluronic acid (HA). The compound or HA is used alone as a polymer or incorporated into a hydrogel for treating body cavity cancer, comprising administering an effective amount of the compound or hydrogel. The invention also provides a method for treating body cavity or soft tissue cancer comprising: introducing into the affected area a thermo reversible gel comprising the compound or HA, allowing the radioactive isotope to emit a therapeutic radiation to affected regions; and, after a predetermined time, optionally removing the gel from the body cavity with a cold rinse to liquefy the gel and allow it to exit the body cavity.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: May 31, 2022
    Inventor: Robert Norman Taub
  • Patent number: 11339212
    Abstract: The present disclosure is based, in part, on the discovery of antibodies that selectively targets human ?-synuclein aggregates such as oligomers/protofibrils, such as BAN0805. BAN0805 has a lower tendency to bind to the undesired monomeric ?-synuclein target as compared to mouse monoclonal antibody mAb47.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: May 24, 2022
    Assignee: BioArctic AB
    Inventors: Eva Nordström, Jessica Sigvardson, Patrik Nygren
  • Patent number: 11339218
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG3. In certain embodiments, the antibodies bind both human and monkey LAG3 but do not bind mouse LAG3. The invention provides anti-LAG3 antibodies that can inhibit the binding of LAG3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for stimulating an immune response, as well as methods for treating cancer using an anti-LAG3 antibody of the invention.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: May 24, 2022
    Assignee: Zhejiang Shimai Pharmaceutical Co., Ltd.
    Inventors: Weizao Chen, Tao Fu, Zuoxiang Xiao
  • Patent number: 11332543
    Abstract: The present invention provides antibody polypeptides with binding specificity for prostate specific antigen (PSA), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: May 17, 2022
    Assignee: FREDAX AB
    Inventors: Amanda Thuy Tran, Anders Axelsson, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Sven-Erik Strand, Urpo Juhani Lamminmäki
  • Patent number: 11325984
    Abstract: The present invention relates to methods for separating target cells from non-target cells using immunorosettes and magnetic particles. The method involves contacting a sample containing target cells and secondary targets such as erythrocytes with an antibody composition which allows immunorosettes of the target cells and the secondary targets to form. The sample is subsequently contacted with a second antibody composition which allows the binding of magnetic particles to the formed immunorosettes and free secondary targets. The immunorosettes and secondary targets labeled with magnetic particles are separated from non-target cells using a magnetic field. The antibody composition optionally contains bifunctional antibodies or tetrameric antibody complexes.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: May 10, 2022
    Assignee: StemCell Technologies Inc.
    Inventor: Andy Isamu Kokaji
  • Patent number: 11319366
    Abstract: The present invention provides an antibody facilitating programmed necrosis of cells. The antibody can cause programmed necrosis of cells in the presence of tumor necrosis factor (TNF). Therefore, an inhibitor for the antibody can be used in the treatment of inflammatory diseases. Further, the present invention provides the application of the antibody facilitating programmed necrosis of cells in the inflammatory disease prognosis.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: May 3, 2022
    Assignee: SHANGHAI JW INFLINHIX CO., LTD.
    Inventors: Shisong Jiang, Wenshu Lu
  • Patent number: 11312784
    Abstract: Disclosed herein are multifunctional antigen-binding proteins comprising at least one multifunctional recombinant protein scaffold and at least one antigen-specific binding domain. Polynucleotides encoding the multifunctional antigen-binding proteins, vectors containing the disclosed polynucleotides, and cells that have been genetically engineered to express the polynucleotide are also provided. Methods of using the multifunctional antigen-binding proteins are disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: April 26, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Hongtao Zhang, Zhiqiang Zhu, Lian Lam, Zheng Cai
  • Patent number: 11298433
    Abstract: Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (VHH), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the VHH, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a ?-emitter and ?-emitter.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: April 12, 2022
    Assignee: VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Tony Lahoutte, Matthias D'Huyvetter, Jens De Vos, Nick Devoogdt
  • Patent number: 11286302
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: March 29, 2022
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein